![Colin Richard Green](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Colin Richard Green
Gründer bei CoDa Therapeutics (NZ) Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Bradford J. Duft | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 Jahre |
David Alan Pool | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | 16 Jahre |
Ted Greene | M | 81 |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 Jahre |
James Mervis | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
David Laurence Becker | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 21 Jahre |
James Blair | M | 84 |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Brian Levy | M | 72 |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Geoff Brooke | M | 68 |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
David Elliot Eisenbud | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
Richard Rubino | M | 66 |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Tracey Sunderland | F | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 18 Jahre |
Anthony Phillips | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
Scott Bannan | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 17 Jahre |
Rajiv Sarman Shukla | M | 49 |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | 5 Jahre |
Mikhail Getman | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | - |
Jason Werner | M | 46 |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Francis John Spurway | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 17 Jahre |
Phil Rosenfeld | M | - |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
David Boyer | M | - |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Bruce Phillips | M | 69 | 20 Jahre | |
Kenneth Williams | M | 63 | - | |
Andy John Hogendijk | M | - | 6 Jahre | |
David McEvoy | M | 77 | 12 Jahre | |
Bruce J. W. Wood | M | 71 | 4 Jahre | |
Dennis Washer | M | - | 9 Jahre | |
Shaun T. McCann | M | - |
Auckland University
| 4 Jahre |
Ka Chuan Ling | M | 66 |
Auckland University
| 4 Jahre |
Yew Wei Yong | M | 71 |
Auckland University
| 4 Jahre |
Melvyn Maylin | M | - |
Auckland University
| 4 Jahre |
Aidan Coleman | M | 68 |
Auckland University
| 4 Jahre |
Kwang Khee Siow | M | 63 |
Auckland University
| 4 Jahre |
To Ching Or | M | - |
Auckland University
| 4 Jahre |
Hong Keong Chiu | M | 69 |
Auckland University
| 4 Jahre |
Voon Yean Ngeow | M | 72 |
Auckland University
| 4 Jahre |
Rina Ciputra Sastrawinata | F | 69 |
Auckland University
| 4 Jahre |
Grove Matsuoka | M | - |
CoDa Therapeutics (NZ) Ltd.
![]() CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | 9 Jahre |
Brodrick Westlake Wray | M | - | 4 Jahre | |
Gary O'Connor | M | 64 |
Auckland University
| 4 Jahre |
Leigh Brooks | M | - | 13 Jahre | |
Rick D. Frith | M | - | - | |
Hoi Chuen Cheng | M | 74 |
Auckland University
| 1 Jahre |
Edward Scott Smith | M | 80 | - | |
Bruce Galloway McKay | M | 73 | 13 Jahre | |
Liong Kim Chew | M | 69 |
Auckland University
| 4 Jahre |
Malcolm Jackman | M | 71 |
Auckland University
| 9 Jahre |
Patrick Strange | M | - |
Auckland University
| 3 Jahre |
Graeme F. Fowler | M | - |
Auckland University
| 1 Jahre |
Andrew Furniss | M | - | 11 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Neuseeland | 30 | 62,50% |
Australien | 12 | 25,00% |
Vereinigte Staaten | 8 | 16,67% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Colin Richard Green
- Persönliches Netzwerk